Latest Sedatives Stories
WILMINGTON, Del., April 8 /PRNewswire-FirstCall/ -- Today, the U.S.
WILMINGTON, Del., April 3 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) is aware that earlier today, the US Food and Drug Administration (FDA) posted to its web site -- and subsequently removed -- briefing documents for the April 8, 2009 Psychopharmacologic Drugs Advisory Committee (PDAC) meeting.
Findings suggest that chronic insomnia is a major public health concern, and its diagnosis and appropriate treatment should become the target of public health policy.
A study of insomnia patients suggests it is a persistent condition that is hard to shake.
About three-fourths of individuals with insomnia report experiencing the condition for at least one year and almost half experience it for three years, according to a report in the March 9 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
'Trial Meets Primary and Key Secondary Endpoints' NEW YORK, March 10 /PRNewswire/ -- Intra-Cellular Therapies, Inc. today announced the final results from the ITI-007 Phase II trial in patients with Sleep Maintenance Insomnia (SMI).
More than 20% of sexual assaults in a sample of 882 victims were drug-facilitated sexual assaults, found a new study published in CMAJ.
British drug maker AstraZeneca denies it tried to downplay side effects of its psychiatric drug Seroquel and market it as if there were no health risks. Lawyers suing AstraZeneca allege the company knew about the risk of weight gain and diabetes in 2000 yet failed to warn doctors and patients, The Wall Street Journal reported Sunday. In documents unsealed last week, a 1997 e-mail message from Richard Lawrence, an AstraZeneca official, praised Lisa Arventis, the Seroquel project physician at...
READING, England, February 26 /PRNewswire/ -- - Intranasal Apomorphine for the Treatment of Motor Fluctuations in Advanced Parkinson's Disease - Intranasal Diazepam for the Treatment of Acute Repetitive Seizures in Epilepsy - Phase II Trials on Both Projects to be Initiated During 2009 Archimedes Pharma Limited, the pan-European specialty pharmaceutical company, today announces positive headline data from its recently completed proof-of-concept trials for two of its...
Nearly every patient who receives care in the intensive care unit (ICU) requires sedation. But, as researchers have discovered, not all sedation medications are equal.